Phase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEK

ACoP 15 (Nov 2024), Poster: W-019
Yamamura A, Axel A, King P, Funt J, Foley EM, Kovar C, Bergstrand M, Mezzalana E, Chenel M, Hayreh V, Hall B.
ConferenceMIDDOncologyPharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Christina-Kovar_Pharmetheus
Director, MIDD Consultant

Christina Kovar

See bio
Portrait-of-Martin-Bergstrand_Pharmetheus
Principal Director, MIDD Scientific Lead

Martin Bergstrand

See bio
Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Director, MIDD Consultant

Enrica Mezzalana

See bio
Portrait-of-Marylore-Chenel_Pharmetheus
Chief Research Officer

Marylore Chenel

See bio